IQ-AI Ltd - London-based medical services company - Amends existing distribution agreement with artificial intelligence platform provider Blackford Analysis Ltd. The amendment adds IB Nimble, IB ASL, IB FTB, and IB FTB Express to the agreement, allowing Blackford to also sell these products to their global client base. Acquired by Bayer in early 2023, Blackford operates in the healthcare AI platform and solutions sphere.
Current stock price: 1.66 pence
12-month change: down 42%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2025 Alliance News Ltd. All Rights Reserved.


IQ-AI Ltd - London-based medical services company - Says subsidiary Imaging Biometrics LLC has applied for breakthrough therapy designation from the U...


IQ-AI Ltd - London-based medical services company - Provides operations update focusing on artificial intelligence. Explains radiology leads the way i...


IQ-AI Ltd - parent of Wisconsin-based Imaging Biometrics LLC, which provides quantitative imaging platforms and therapeutics for the diagnosis and tre...


IQ-AI Ltd - London-based medical services company - Says subsidiary Imaging Biometrics LLC has applied for breakthrough therapy designation from the U...


IQ-AI Ltd - London-based medical services company - Amends existing distribution agreement with artificial intelligence platform provider Blackford An...


IQ-AI Ltd - London-based medical services company - Provides operations update focusing on artificial intelligence. Explains radiology leads the way i...


IQ-AI Ltd - parent of Wisconsin-based Imaging Biometrics LLC, which provides quantitative imaging platforms and therapeutics for the diagnosis and tre...


(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and Wednesday and not separately reported by Al...


IQ-AI Ltd - London-based medical services company - US-based subsidiary Imaging Biometrics LLC says that US Food & Drug Administration has approved an...


(Alliance News) - IQ-AI Ltd on Friday said the clinical team has started a phase 2 protocol for its oncology-focused drug oral gallium maltolate, whic...


(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: